Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Oct 19, 2026
TickeronGET DAILY SIGNALS
Why Is Glass House Brands (GLAS) Stock Down -40.44% Today?

Why Is Glass House Brands (GLAS) Stock Down -40.44% Today?

Key Takeaways

  • GLAS shares plunged roughly 40% intraday after the company pre-announced third-quarter results.
  • The primary catalyst was sharp margin compression, with average selling price falling to $150 per pound from $211 per pound in the prior quarter.
  • Record production and revenue were overshadowed by a deteriorating California wholesale cannabis pricing environment.
  • A surprise board resignation added a layer of governance uncertainty to the selloff.
  • Traders are watching for price stabilization and the company's next scheduled earnings report.

Opening Summary

Glass House Brands Inc. (GLAS), a vertically integrated California-focused cannabis cultivator and consumer packaged goods company, saw its shares crater on Monday after releasing preliminary third-quarter financial results. The stock traded down roughly 40.44% to approximately $1.90 in morning trading, compared with a prior-session close of $3.19 on Friday, October 16. The move confirmed a steep decline driven by sharply weaker wholesale pricing and gross-margin compression, despite headline revenue and production figures that came in ahead of expectations.

Q3 Preliminary Results: Pricing Pressure Hits Margins

The selloff traces directly to the company's pre-announcement of unaudited results for the quarter ended September 30, 2026. Glass House reported revenue of $56.8 million, up 21% sequentially from $47.0 million and more than double the $26.2 million reported a year earlier, and record biomass production of approximately 317,000 pounds. Yet the market focused on the deterioration in unit economics: average wholesale selling price dropped to $150 per pound from $211 per pound in the second quarter, a decline of roughly 29%, while gross margin narrowed to 26% from 34%.

The result was gross profit of $14.9 million, essentially flat quarter over quarter despite materially higher volume, and operating cash flow that turned slightly negative at -$0.4 million versus +$0.2 million in the prior quarter. Management attributed the compression to a trim-heavy sales mix and seasonal pricing weakness in California. Investors interpreted the data as a sign that volume growth is being absorbed by falling prices rather than converting into improved profitability.

Deteriorating California Wholesale Pricing and Sector Sentiment

Beyond the company's own figures, the move reflects a broader malaise in the California wholesale cannabis market. Pricing has been under sustained pressure as supply remains plentiful, compressing margins across operators even as Glass House continues to lower its cost of production, which fell roughly 10% sequentially to about $110 per pound. The company reaffirmed its full-year 2026 production target of approximately one million pounds and its long-term goal of $95 per pound, but those efficiency gains have not been enough to offset the decline in realized prices.

The share-price reaction also echoes sentiment across the cannabis sector, which has traded with elevated volatility and sensitivity to capital availability and regulatory expectations. As a lower-priced, relatively thinly traded name near its 52-week low, GLAS is prone to outsized percentage moves when selling pressure builds.

Board Departure Adds to Governance Concerns

Compounding the negative reaction, the company disclosed that director John Nichols Jr. resigned from the board, with no reason provided in the announcement. The departure follows a run of recent governance and management changes, including a previously announced CFO retirement and an auditor change, adding an element of uncertainty that weighed on sentiment alongside the weak margin data.

Market Context and Trading Activity

Trading volume was elevated relative to the stock's recent average as investors absorbed the pre-announcement. The decline pushed shares well below their 50-day and 200-day moving averages and toward the lower end of a 52-week range of roughly $3.10 to $13.93. The move diverged from the broader tape and is best understood as a company- and sector-specific repricing rather than a reflection of general equity-market conditions. The stock's low absolute price and concentrated trading profile likely amplified the percentage decline.

What Comes Next for GLAS

Attention now turns to whether management can stabilize realized pricing and demonstrate a credible path to positive cash flow. The company ended the quarter with about $39.7 million in cash and said it has turned off its at-the-market equity program after raising capital earlier in the year, which reduces near-term dilution risk but leaves execution on margin recovery as the key variable. Upcoming earnings and any further commentary on California pricing, the greenhouse optimization program, and the timeline for reaching cash-flow breakeven will be closely watched. Risks include continued wholesale price erosion, financing conditions, and the absence of fresh regulatory catalysts for the cannabis sector.

Trending AI Robots

For traders seeking a data-driven edge across volatile names like GLAS, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing automated strategies. Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only those delivering standout results under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to evaluate approaches that fit their own objectives. Explore the Trending AI Robots page to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GLAS

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


GLAS's Stochastic Oscillator sits in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Moving Average Convergence Divergence (MACD) for GLAS just turned positive on October 28, 2026. Looking at past instances where GLAS's MACD turned positive, the stock continued to rise in 27 of 36 cases over the following month. The odds of a continued upward trend are 75%.

GLAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLAS as a result. In 69 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for GLAS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.699) is normal, around the industry mean (6.379). P/E Ratio (-2.737) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.880) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. GLAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -0%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 10%. XERS experienced the highest price growth at 53%, while AKAN experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 10%. For the same stocks of the Industry, the average monthly volume growth was 21% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 55
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
3645 Long Beach Boulevard
Phone
+1 212 299-7670
Employees
428
Web
https://www.glasshousebrands.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
XRPN fell -9.70% in early regular-session trading on Tuesday, sliding from Monday's $10.41 close to $9.40. The decline follows a November 9 SEC prospectus disclosing a committed equity facility with Cantor to sell up to 5.2 million new Class A shares at 97% of the volume-weighted average price, implying up to roughly 16.7% potential dilution.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.
Why Is Glass House Brands (GLAS) Stock Down -40.44% Today?